Neurogene Inc. — Director's Dealing 2020

Jun 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Neoleukin Therapeutics, Inc. (NLTX)
CIK: 0001404644
Period of Report: 2020-06-01

Reporting Person: Lavelle Erin M. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-01	Stock Option (Right to Buy)	$13.58	A	50000	Acquired	2030-06-01	Common Stock (50000)	Direct

Footnotes

F1: The option vests as to 1/3 of the total shares on each of June 1, 2021, June 1, 2022 and June 1, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.